Camurus AB (publ) 7CA.F Stock
Camurus AB (publ) Price Chart
Camurus AB (publ) 7CA.F Financial and Trading Overview
| Camurus AB (publ) stock price | 44.28 EUR |
| Previous Close | 23.98 EUR |
| Open | 24.08 EUR |
| Bid | 24.14 EUR x 100000 |
| Ask | 24.32 EUR x 100000 |
| Day's Range | 24.08 - 24.08 EUR |
| 52 Week Range | 16.71 - 25.32 EUR |
| Volume | 150 EUR |
| Avg. Volume | 29 EUR |
| Market Cap | 1.42B EUR |
| Beta (5Y Monthly) | 0.937164 |
| PE Ratio (TTM) | 141.64706 |
| EPS (TTM) | 0.65 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
7CA.F Valuation Measures
| Enterprise Value | 1.31B EUR |
| Trailing P/E | 141.64706 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 24.176706 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Camurus AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.937164 |
| 52-Week Change | 42.54% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 25.32 EUR |
| 52 Week Low | 16.71 EUR |
| 50-Day Moving Average | 21.34 EUR |
| 200-Day Moving Average | 21.83 EUR |
7CA.F Share Statistics
| Avg. Volume (3 month) | 29 EUR |
| Avg. Daily Volume (10-Days) | 7 EUR |
| Shares Outstanding | 55.46M |
| Float | 29.29M |
| Short Ratio | N/A |
| % Held by Insiders | 51.45% |
| % Held by Institutions | 21.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 11.28% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 89.62% |
| EBITDA Margin | 14.05% |
Management Effectiveness
| Return on Assets (ttm) | 7.20% |
| Return on Equity (ttm) | 12.02% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | 28.89% |
| Gross Profit (ttm) | 853.08M EUR |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | N/A |
| Diluted EPS (ttm) | 0.17 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | 2.26 EUR |
| Current Ratio (mrq) | 3.696 |
| Book Value Per Share (mrq) | 0.996 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Camurus AB (publ)
| Country | Germany |
| State | N/A |
| City | Lund |
| Address | Ideon Science Park |
| ZIP | 223 70 |
| Phone | 46 4 62 86 57 30 |
| Website | https://www.camurus.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 188 |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden. Camurus AB (publ) was formerly a subsidiary of Sandberg Development AB.
Q&A For Camurus AB (publ) Stock
What is a current 7CA.F stock price?
Camurus AB (publ) 7CA.F stock price today per share is 44.28 EUR.
How to purchase Camurus AB (publ) stock?
You can buy 7CA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Camurus AB (publ)?
The stock symbol or ticker of Camurus AB (publ) is 7CA.F.
Which industry does the Camurus AB (publ) company belong to?
The Camurus AB (publ) industry is Biotechnology.
How many shares does Camurus AB (publ) have in circulation?
The max supply of Camurus AB (publ) shares is 57.62M.
What is Camurus AB (publ) Price to Earnings Ratio (PE Ratio)?
Camurus AB (publ) PE Ratio is 68.12308000 now.
What was Camurus AB (publ) earnings per share over the trailing 12 months (TTM)?
Camurus AB (publ) EPS is 0.65 EUR over the trailing 12 months.
Which sector does the Camurus AB (publ) company belong to?
The Camurus AB (publ) sector is Healthcare.